nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrimeprazine—ADRA1B—vas deferens—urinary bladder cancer	0.158	0.251	CbGeAlD
Methotrimeprazine—CHRM3—ureter—urinary bladder cancer	0.0742	0.118	CbGeAlD
Methotrimeprazine—CHRM3—muscle of abdomen—urinary bladder cancer	0.0534	0.0847	CbGeAlD
Methotrimeprazine—Necrotising colitis—Epirubicin—urinary bladder cancer	0.0239	0.108	CcSEcCtD
Methotrimeprazine—Necrotising colitis—Doxorubicin—urinary bladder cancer	0.0221	0.0999	CcSEcCtD
Methotrimeprazine—CYP1A2—urine—urinary bladder cancer	0.0183	0.029	CbGeAlD
Methotrimeprazine—CYP2E1—urine—urinary bladder cancer	0.0165	0.0261	CbGeAlD
Methotrimeprazine—HTR2A—urine—urinary bladder cancer	0.0143	0.0227	CbGeAlD
Methotrimeprazine—ADRA1D—prostate gland—urinary bladder cancer	0.0138	0.0219	CbGeAlD
Methotrimeprazine—Urinary retention—Valrubicin—urinary bladder cancer	0.0136	0.0616	CcSEcCtD
Methotrimeprazine—CYP2D6—urine—urinary bladder cancer	0.013	0.0207	CbGeAlD
Methotrimeprazine—CHRM5—epithelium—urinary bladder cancer	0.0114	0.018	CbGeAlD
Methotrimeprazine—Sudden death—Fluorouracil—urinary bladder cancer	0.0111	0.05	CcSEcCtD
Methotrimeprazine—CHRM2—prostate gland—urinary bladder cancer	0.0106	0.0168	CbGeAlD
Methotrimeprazine—ADRA1D—epithelium—urinary bladder cancer	0.0102	0.0161	CbGeAlD
Methotrimeprazine—CHRM1—prostate gland—urinary bladder cancer	0.00967	0.0153	CbGeAlD
Methotrimeprazine—ADRA1B—renal system—urinary bladder cancer	0.00964	0.0153	CbGeAlD
Methotrimeprazine—DRD5—female reproductive system—urinary bladder cancer	0.00941	0.0149	CbGeAlD
Methotrimeprazine—ADRA1D—urethra—urinary bladder cancer	0.00926	0.0147	CbGeAlD
Methotrimeprazine—CHRM3—prostate gland—urinary bladder cancer	0.00865	0.0137	CbGeAlD
Methotrimeprazine—ADRA1A—prostate gland—urinary bladder cancer	0.00794	0.0126	CbGeAlD
Methotrimeprazine—Drowsiness—Mitomycin—urinary bladder cancer	0.00761	0.0344	CcSEcCtD
Methotrimeprazine—ADRA2C—prostate gland—urinary bladder cancer	0.00757	0.012	CbGeAlD
Methotrimeprazine—ADRA1D—female reproductive system—urinary bladder cancer	0.00755	0.012	CbGeAlD
Methotrimeprazine—ADRA2C—seminal vesicle—urinary bladder cancer	0.0064	0.0102	CbGeAlD
Methotrimeprazine—Liver injury—Cisplatin—urinary bladder cancer	0.00638	0.0288	CcSEcCtD
Methotrimeprazine—Drug interaction—Gemcitabine—urinary bladder cancer	0.00621	0.028	CcSEcCtD
Methotrimeprazine—HRH1—prostate gland—urinary bladder cancer	0.00615	0.00975	CbGeAlD
Methotrimeprazine—CHRM3—smooth muscle tissue—urinary bladder cancer	0.00613	0.00971	CbGeAlD
Methotrimeprazine—ADRA2A—prostate gland—urinary bladder cancer	0.00604	0.00958	CbGeAlD
Methotrimeprazine—CYP2E1—prostate gland—urinary bladder cancer	0.00591	0.00937	CbGeAlD
Methotrimeprazine—CHRM3—renal system—urinary bladder cancer	0.0059	0.00935	CbGeAlD
Methotrimeprazine—ADRA1A—epithelium—urinary bladder cancer	0.00584	0.00926	CbGeAlD
Methotrimeprazine—CHRM3—urethra—urinary bladder cancer	0.00579	0.00919	CbGeAlD
Methotrimeprazine—Sudden death—Methotrexate—urinary bladder cancer	0.00576	0.026	CcSEcCtD
Methotrimeprazine—HTR2C—female reproductive system—urinary bladder cancer	0.00559	0.00886	CbGeAlD
Methotrimeprazine—ADRA1A—renal system—urinary bladder cancer	0.00541	0.00859	CbGeAlD
Methotrimeprazine—Hepatocellular injury—Cisplatin—urinary bladder cancer	0.00537	0.0242	CcSEcCtD
Methotrimeprazine—CHRM1—female reproductive system—urinary bladder cancer	0.00528	0.00837	CbGeAlD
Methotrimeprazine—ADRA2C—renal system—urinary bladder cancer	0.00516	0.00818	CbGeAlD
Methotrimeprazine—ADRA2A—seminal vesicle—urinary bladder cancer	0.00511	0.0081	CbGeAlD
Methotrimeprazine—ADRA2C—urethra—urinary bladder cancer	0.00507	0.00804	CbGeAlD
Methotrimeprazine—CYP2E1—seminal vesicle—urinary bladder cancer	0.005	0.00793	CbGeAlD
Methotrimeprazine—Urinary retention—Thiotepa—urinary bladder cancer	0.00472	0.0213	CcSEcCtD
Methotrimeprazine—CHRM3—female reproductive system—urinary bladder cancer	0.00472	0.00749	CbGeAlD
Methotrimeprazine—Photosensitivity—Fluorouracil—urinary bladder cancer	0.00468	0.0211	CcSEcCtD
Methotrimeprazine—HRH1—epithelium—urinary bladder cancer	0.00452	0.00717	CbGeAlD
Methotrimeprazine—CYP1A2—renal system—urinary bladder cancer	0.00448	0.0071	CbGeAlD
Methotrimeprazine—HRH1—smooth muscle tissue—urinary bladder cancer	0.00435	0.0069	CbGeAlD
Methotrimeprazine—Somnolence—Mitomycin—urinary bladder cancer	0.00432	0.0195	CcSEcCtD
Methotrimeprazine—HRH1—urethra—urinary bladder cancer	0.00412	0.00653	CbGeAlD
Methotrimeprazine—ADRA2A—urethra—urinary bladder cancer	0.00404	0.00641	CbGeAlD
Methotrimeprazine—CYP2E1—renal system—urinary bladder cancer	0.00403	0.00639	CbGeAlD
Methotrimeprazine—CYP2E1—urethra—urinary bladder cancer	0.00396	0.00627	CbGeAlD
Methotrimeprazine—Weight increased—Thiotepa—urinary bladder cancer	0.00391	0.0177	CcSEcCtD
Methotrimeprazine—HTR2A—epithelium—urinary bladder cancer	0.00377	0.00598	CbGeAlD
Methotrimeprazine—ADRA2C—vagina—urinary bladder cancer	0.00374	0.00593	CbGeAlD
Methotrimeprazine—Jaundice—Thiotepa—urinary bladder cancer	0.00373	0.0169	CcSEcCtD
Methotrimeprazine—HTR2A—smooth muscle tissue—urinary bladder cancer	0.00364	0.00577	CbGeAlD
Methotrimeprazine—Agranulocytosis—Thiotepa—urinary bladder cancer	0.00357	0.0161	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Cisplatin—urinary bladder cancer	0.00356	0.0161	CcSEcCtD
Methotrimeprazine—HTR2A—renal system—urinary bladder cancer	0.0035	0.00555	CbGeAlD
Methotrimeprazine—HRH1—female reproductive system—urinary bladder cancer	0.00336	0.00532	CbGeAlD
Methotrimeprazine—ADRA2A—female reproductive system—urinary bladder cancer	0.0033	0.00523	CbGeAlD
Methotrimeprazine—Liver injury—Epirubicin—urinary bladder cancer	0.00328	0.0148	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Fluorouracil—urinary bladder cancer	0.00324	0.0146	CcSEcCtD
Methotrimeprazine—CYP2E1—female reproductive system—urinary bladder cancer	0.00323	0.00511	CbGeAlD
Methotrimeprazine—CYP2D6—renal system—urinary bladder cancer	0.00319	0.00506	CbGeAlD
Methotrimeprazine—HRH1—vagina—urinary bladder cancer	0.00304	0.00481	CbGeAlD
Methotrimeprazine—Liver injury—Doxorubicin—urinary bladder cancer	0.00303	0.0137	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Gemcitabine—urinary bladder cancer	0.00301	0.0136	CcSEcCtD
Methotrimeprazine—ADRA2A—vagina—urinary bladder cancer	0.00298	0.00473	CbGeAlD
Methotrimeprazine—Agranulocytosis—Fluorouracil—urinary bladder cancer	0.00296	0.0133	CcSEcCtD
Methotrimeprazine—HTR2A—female reproductive system—urinary bladder cancer	0.0028	0.00445	CbGeAlD
Methotrimeprazine—Hepatocellular injury—Epirubicin—urinary bladder cancer	0.00276	0.0124	CcSEcCtD
Methotrimeprazine—Jaundice—Etoposide—urinary bladder cancer	0.00268	0.0121	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Etoposide—urinary bladder cancer	0.00257	0.0116	CcSEcCtD
Methotrimeprazine—CYP2D6—female reproductive system—urinary bladder cancer	0.00255	0.00405	CbGeAlD
Methotrimeprazine—Hepatocellular injury—Doxorubicin—urinary bladder cancer	0.00255	0.0115	CcSEcCtD
Methotrimeprazine—HTR2A—vagina—urinary bladder cancer	0.00254	0.00402	CbGeAlD
Methotrimeprazine—Photosensitivity—Methotrexate—urinary bladder cancer	0.00243	0.011	CcSEcCtD
Methotrimeprazine—ADRA2C—lymph node—urinary bladder cancer	0.00242	0.00383	CbGeAlD
Methotrimeprazine—Tachycardia—Thiotepa—urinary bladder cancer	0.00238	0.0108	CcSEcCtD
Methotrimeprazine—Photosensitivity—Epirubicin—urinary bladder cancer	0.00228	0.0103	CcSEcCtD
Methotrimeprazine—Somnolence—Thiotepa—urinary bladder cancer	0.00217	0.00981	CcSEcCtD
Methotrimeprazine—Photosensitivity—Doxorubicin—urinary bladder cancer	0.00211	0.00952	CcSEcCtD
Methotrimeprazine—Constipation—Thiotepa—urinary bladder cancer	0.00209	0.00943	CcSEcCtD
Methotrimeprazine—Tachycardia—Fluorouracil—urinary bladder cancer	0.00197	0.0089	CcSEcCtD
Methotrimeprazine—HRH1—lymph node—urinary bladder cancer	0.00196	0.00311	CbGeAlD
Methotrimeprazine—ADRA2A—lymph node—urinary bladder cancer	0.00193	0.00306	CbGeAlD
Methotrimeprazine—Tachycardia—Cisplatin—urinary bladder cancer	0.00187	0.00844	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Epirubicin—urinary bladder cancer	0.00183	0.00825	CcSEcCtD
Methotrimeprazine—Somnolence—Gemcitabine—urinary bladder cancer	0.00183	0.00825	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.0018	0.00813	CcSEcCtD
Methotrimeprazine—Somnolence—Fluorouracil—urinary bladder cancer	0.0018	0.00811	CcSEcCtD
Methotrimeprazine—Constipation—Gemcitabine—urinary bladder cancer	0.00176	0.00793	CcSEcCtD
Methotrimeprazine—Tachycardia—Etoposide—urinary bladder cancer	0.00171	0.00773	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Doxorubicin—urinary bladder cancer	0.00169	0.00764	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.00169	0.00762	CcSEcCtD
Methotrimeprazine—Drowsiness—Methotrexate—urinary bladder cancer	0.00165	0.00744	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.00158	0.00713	CcSEcCtD
Methotrimeprazine—Weight increased—Epirubicin—urinary bladder cancer	0.00157	0.00711	CcSEcCtD
Methotrimeprazine—Somnolence—Etoposide—urinary bladder cancer	0.00156	0.00704	CcSEcCtD
Methotrimeprazine—Drowsiness—Epirubicin—urinary bladder cancer	0.00154	0.00696	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Methotrexate—urinary bladder cancer	0.00154	0.00694	CcSEcCtD
Methotrimeprazine—Jaundice—Epirubicin—urinary bladder cancer	0.0015	0.00679	CcSEcCtD
Methotrimeprazine—Constipation—Etoposide—urinary bladder cancer	0.0015	0.00678	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00149	0.00672	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.00146	0.0066	CcSEcCtD
Methotrimeprazine—Weight increased—Doxorubicin—urinary bladder cancer	0.00146	0.00658	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Epirubicin—urinary bladder cancer	0.00144	0.0065	CcSEcCtD
Methotrimeprazine—Drowsiness—Doxorubicin—urinary bladder cancer	0.00143	0.00644	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00141	0.00637	CcSEcCtD
Methotrimeprazine—Jaundice—Doxorubicin—urinary bladder cancer	0.00139	0.00628	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.00133	0.00601	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Etoposide—urinary bladder cancer	0.00129	0.00584	CcSEcCtD
Methotrimeprazine—Tachycardia—Epirubicin—urinary bladder cancer	0.00096	0.00433	CcSEcCtD
Methotrimeprazine—Somnolence—Methotrexate—urinary bladder cancer	0.000934	0.00422	CcSEcCtD
Methotrimeprazine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000888	0.00401	CcSEcCtD
Methotrimeprazine—Somnolence—Epirubicin—urinary bladder cancer	0.000874	0.00395	CcSEcCtD
Methotrimeprazine—Constipation—Epirubicin—urinary bladder cancer	0.000841	0.0038	CcSEcCtD
Methotrimeprazine—Somnolence—Doxorubicin—urinary bladder cancer	0.000809	0.00365	CcSEcCtD
Methotrimeprazine—Constipation—Doxorubicin—urinary bladder cancer	0.000778	0.00351	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000774	0.0035	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000724	0.00327	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.00067	0.00303	CcSEcCtD
Methotrimeprazine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.11e-05	0.000143	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—EP300—urinary bladder cancer	2.11e-05	0.000142	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—CXCL8—urinary bladder cancer	2.1e-05	0.000142	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Metabolism—EP300—urinary bladder cancer	2.1e-05	0.000142	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling by GPCR—KRAS—urinary bladder cancer	2.1e-05	0.000142	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	2.09e-05	0.000141	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—IL2—urinary bladder cancer	2.09e-05	0.000141	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CREBBP—urinary bladder cancer	2.09e-05	0.000141	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling by GPCR—KRAS—urinary bladder cancer	2.09e-05	0.000141	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling by GPCR—HRAS—urinary bladder cancer	2.09e-05	0.000141	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—RHOA—urinary bladder cancer	2.08e-05	0.00014	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—EP300—urinary bladder cancer	2.08e-05	0.00014	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—EP300—urinary bladder cancer	2.08e-05	0.00014	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—RHOA—urinary bladder cancer	2.08e-05	0.00014	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—RHOA—urinary bladder cancer	2.07e-05	0.00014	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—IGF1—urinary bladder cancer	2.07e-05	0.00014	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—RHOA—urinary bladder cancer	2.06e-05	0.000139	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—EGFR—urinary bladder cancer	2.06e-05	0.000139	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—SRC—urinary bladder cancer	2.05e-05	0.000138	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—PTGS2—urinary bladder cancer	2.05e-05	0.000138	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—CXCL8—urinary bladder cancer	2.04e-05	0.000138	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—RHOA—urinary bladder cancer	2.04e-05	0.000138	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—MYC—urinary bladder cancer	2.04e-05	0.000138	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—CCND1—urinary bladder cancer	2.04e-05	0.000138	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—RHOA—urinary bladder cancer	2.04e-05	0.000138	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling by GPCR—HRAS—urinary bladder cancer	2.03e-05	0.000137	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—TYMS—urinary bladder cancer	2.03e-05	0.000137	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—SRC—urinary bladder cancer	2.02e-05	0.000137	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—SRC—urinary bladder cancer	2.02e-05	0.000137	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—CXCL8—urinary bladder cancer	2.01e-05	0.000136	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—MYC—urinary bladder cancer	2.01e-05	0.000136	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—IL2—urinary bladder cancer	2.01e-05	0.000136	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	2.01e-05	0.000135	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	2.01e-05	0.000135	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling by GPCR—HRAS—urinary bladder cancer	2e-05	0.000135	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—EGFR—urinary bladder cancer	2e-05	0.000135	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—MMP9—urinary bladder cancer	1.98e-05	0.000134	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—CDKN1A—urinary bladder cancer	1.97e-05	0.000133	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—PTEN—urinary bladder cancer	1.97e-05	0.000133	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—EGFR—urinary bladder cancer	1.97e-05	0.000133	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—CCND1—urinary bladder cancer	1.96e-05	0.000132	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—ERBB2—urinary bladder cancer	1.96e-05	0.000132	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—IL2—urinary bladder cancer	1.95e-05	0.000132	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—PTEN—urinary bladder cancer	1.95e-05	0.000132	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—KRAS—urinary bladder cancer	1.94e-05	0.000131	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—MYC—urinary bladder cancer	1.93e-05	0.00013	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—ERBB2—urinary bladder cancer	1.93e-05	0.00013	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—IL2—urinary bladder cancer	1.92e-05	0.00013	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—ERBB2—urinary bladder cancer	1.92e-05	0.00013	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—GPX1—urinary bladder cancer	1.92e-05	0.00013	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—ERBB2—urinary bladder cancer	1.91e-05	0.000129	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—ERBB2—urinary bladder cancer	1.91e-05	0.000129	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—CCND1—urinary bladder cancer	1.91e-05	0.000129	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—MMP9—urinary bladder cancer	1.9e-05	0.000128	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—CDKN1A—urinary bladder cancer	1.89e-05	0.000128	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—RHOA—urinary bladder cancer	1.89e-05	0.000128	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—PTEN—urinary bladder cancer	1.89e-05	0.000128	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—ERBB2—urinary bladder cancer	1.89e-05	0.000128	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	1.89e-05	0.000127	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—EGFR—urinary bladder cancer	1.89e-05	0.000127	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—ERBB2—urinary bladder cancer	1.89e-05	0.000127	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—KRAS—urinary bladder cancer	1.89e-05	0.000127	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—PTGS2—urinary bladder cancer	1.88e-05	0.000127	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—EP300—urinary bladder cancer	1.88e-05	0.000127	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—CCND1—urinary bladder cancer	1.88e-05	0.000127	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—KRAS—urinary bladder cancer	1.86e-05	0.000126	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—EP300—urinary bladder cancer	1.86e-05	0.000125	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—CXCL8—urinary bladder cancer	1.86e-05	0.000125	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—MMP9—urinary bladder cancer	1.85e-05	0.000125	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling by GPCR—HRAS—urinary bladder cancer	1.84e-05	0.000125	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—CDKN1A—urinary bladder cancer	1.84e-05	0.000125	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—PTEN—urinary bladder cancer	1.84e-05	0.000124	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—MYC—urinary bladder cancer	1.84e-05	0.000124	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—CXCL8—urinary bladder cancer	1.83e-05	0.000123	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—SRC—urinary bladder cancer	1.83e-05	0.000123	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—CXCL8—urinary bladder cancer	1.82e-05	0.000123	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—MMP9—urinary bladder cancer	1.82e-05	0.000123	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—CXCL8—urinary bladder cancer	1.82e-05	0.000123	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling by GPCR—HRAS—urinary bladder cancer	1.81e-05	0.000123	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—CDKN1A—urinary bladder cancer	1.81e-05	0.000123	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—MYC—urinary bladder cancer	1.81e-05	0.000122	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—MYC—urinary bladder cancer	1.81e-05	0.000122	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—CXCL8—urinary bladder cancer	1.81e-05	0.000122	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling by GPCR—HRAS—urinary bladder cancer	1.81e-05	0.000122	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—PTEN—urinary bladder cancer	1.81e-05	0.000122	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling by GPCR—HRAS—urinary bladder cancer	1.8e-05	0.000122	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—EP300—urinary bladder cancer	1.8e-05	0.000122	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling by GPCR—HRAS—urinary bladder cancer	1.8e-05	0.000121	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—EGFR—urinary bladder cancer	1.8e-05	0.000121	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—CXCL8—urinary bladder cancer	1.79e-05	0.000121	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—CXCL8—urinary bladder cancer	1.79e-05	0.000121	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—PTEN—urinary bladder cancer	1.79e-05	0.000121	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling by GPCR—HRAS—urinary bladder cancer	1.78e-05	0.00012	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—KRAS—urinary bladder cancer	1.78e-05	0.00012	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling by GPCR—HRAS—urinary bladder cancer	1.78e-05	0.00012	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—IL2—urinary bladder cancer	1.77e-05	0.00012	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	1.77e-05	0.00012	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—EGFR—urinary bladder cancer	1.77e-05	0.00012	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—EGFR—urinary bladder cancer	1.77e-05	0.00012	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—EP300—urinary bladder cancer	1.75e-05	0.000118	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—SRC—urinary bladder cancer	1.75e-05	0.000118	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—ERBB2—urinary bladder cancer	1.75e-05	0.000118	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—IL2—urinary bladder cancer	1.74e-05	0.000118	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—IL2—urinary bladder cancer	1.74e-05	0.000118	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—IL2—urinary bladder cancer	1.74e-05	0.000117	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—IL2—urinary bladder cancer	1.73e-05	0.000117	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—CCND1—urinary bladder cancer	1.73e-05	0.000117	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—EP300—urinary bladder cancer	1.73e-05	0.000117	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—IL2—urinary bladder cancer	1.71e-05	0.000116	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—IL2—urinary bladder cancer	1.71e-05	0.000115	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—SRC—urinary bladder cancer	1.71e-05	0.000115	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—EP300—urinary bladder cancer	1.7e-05	0.000115	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—CCND1—urinary bladder cancer	1.7e-05	0.000115	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—CCND1—urinary bladder cancer	1.7e-05	0.000115	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—KRAS—urinary bladder cancer	1.7e-05	0.000115	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.7e-05	0.000115	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—CCND1—urinary bladder cancer	1.69e-05	0.000114	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—CCND1—urinary bladder cancer	1.69e-05	0.000114	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—SRC—urinary bladder cancer	1.68e-05	0.000113	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—MMP9—urinary bladder cancer	1.68e-05	0.000113	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—TP53—urinary bladder cancer	1.68e-05	0.000113	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—KRAS—urinary bladder cancer	1.67e-05	0.000113	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—KRAS—urinary bladder cancer	1.67e-05	0.000113	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.67e-05	0.000113	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—CCND1—urinary bladder cancer	1.67e-05	0.000113	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—PTEN—urinary bladder cancer	1.67e-05	0.000113	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—CCND1—urinary bladder cancer	1.67e-05	0.000113	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CXCL8—urinary bladder cancer	1.66e-05	0.000112	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—TP53—urinary bladder cancer	1.65e-05	0.000112	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—MMP9—urinary bladder cancer	1.65e-05	0.000112	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—HRAS—urinary bladder cancer	1.65e-05	0.000111	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—MMP9—urinary bladder cancer	1.65e-05	0.000111	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.65e-05	0.000111	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—MMP9—urinary bladder cancer	1.64e-05	0.000111	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.64e-05	0.000111	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—PTEN—urinary bladder cancer	1.64e-05	0.000111	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—PTEN—urinary bladder cancer	1.64e-05	0.000111	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—PTEN—urinary bladder cancer	1.64e-05	0.000111	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—MMP9—urinary bladder cancer	1.64e-05	0.000111	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.64e-05	0.000111	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—MYC—urinary bladder cancer	1.64e-05	0.000111	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—PTEN—urinary bladder cancer	1.63e-05	0.00011	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—CDKN1A—urinary bladder cancer	1.63e-05	0.00011	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.63e-05	0.00011	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—PTEN—urinary bladder cancer	1.63e-05	0.00011	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—MMP9—urinary bladder cancer	1.62e-05	0.00011	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—MMP9—urinary bladder cancer	1.62e-05	0.000109	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.62e-05	0.000109	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—PTEN—urinary bladder cancer	1.61e-05	0.000109	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.61e-05	0.000109	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—PTEN—urinary bladder cancer	1.61e-05	0.000109	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—HRAS—urinary bladder cancer	1.6e-05	0.000108	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—EGFR—urinary bladder cancer	1.6e-05	0.000108	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—EP300—urinary bladder cancer	1.59e-05	0.000107	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—IL2—urinary bladder cancer	1.59e-05	0.000107	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—TP53—urinary bladder cancer	1.58e-05	0.000107	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—HRAS—urinary bladder cancer	1.58e-05	0.000107	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—MYC—urinary bladder cancer	1.57e-05	0.000106	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—EP300—urinary bladder cancer	1.57e-05	0.000106	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—EP300—urinary bladder cancer	1.56e-05	0.000106	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—EP300—urinary bladder cancer	1.56e-05	0.000106	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—EP300—urinary bladder cancer	1.56e-05	0.000105	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—EP300—urinary bladder cancer	1.55e-05	0.000105	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CCND1—urinary bladder cancer	1.55e-05	0.000105	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—SRC—urinary bladder cancer	1.55e-05	0.000105	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—EP300—urinary bladder cancer	1.54e-05	0.000104	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—EGFR—urinary bladder cancer	1.54e-05	0.000104	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—EP300—urinary bladder cancer	1.53e-05	0.000104	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—MYC—urinary bladder cancer	1.53e-05	0.000103	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—SRC—urinary bladder cancer	1.52e-05	0.000103	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—SRC—urinary bladder cancer	1.52e-05	0.000103	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—SRC—urinary bladder cancer	1.51e-05	0.000102	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—HRAS—urinary bladder cancer	1.51e-05	0.000102	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—KRAS—urinary bladder cancer	1.51e-05	0.000102	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—SRC—urinary bladder cancer	1.51e-05	0.000102	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—TP53—urinary bladder cancer	1.51e-05	0.000102	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—MYC—urinary bladder cancer	1.5e-05	0.000102	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—MMP9—urinary bladder cancer	1.5e-05	0.000101	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.5e-05	0.000101	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—SRC—urinary bladder cancer	1.49e-05	0.000101	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—EGFR—urinary bladder cancer	1.49e-05	0.000101	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—PTEN—urinary bladder cancer	1.49e-05	0.000101	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—SRC—urinary bladder cancer	1.49e-05	0.000101	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—TP53—urinary bladder cancer	1.49e-05	0.000101	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—TP53—urinary bladder cancer	1.49e-05	0.000101	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—EGFR—urinary bladder cancer	1.47e-05	9.94e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—KRAS—urinary bladder cancer	1.45e-05	9.81e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—HRAS—urinary bladder cancer	1.44e-05	9.74e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PPARG—urinary bladder cancer	1.44e-05	9.71e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—EP300—urinary bladder cancer	1.42e-05	9.62e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—HRAS—urinary bladder cancer	1.42e-05	9.61e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—HRAS—urinary bladder cancer	1.42e-05	9.61e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—KRAS—urinary bladder cancer	1.41e-05	9.54e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—KRAS—urinary bladder cancer	1.39e-05	9.39e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—MYC—urinary bladder cancer	1.39e-05	9.37e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—SRC—urinary bladder cancer	1.39e-05	9.36e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	1.38e-05	9.33e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—MYC—urinary bladder cancer	1.36e-05	9.22e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—MYC—urinary bladder cancer	1.36e-05	9.2e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—MYC—urinary bladder cancer	1.36e-05	9.17e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—EGFR—urinary bladder cancer	1.36e-05	9.16e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—MYC—urinary bladder cancer	1.35e-05	9.14e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—TP53—urinary bladder cancer	1.34e-05	9.08e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—MYC—urinary bladder cancer	1.34e-05	9.05e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—MYC—urinary bladder cancer	1.34e-05	9.02e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.33e-05	9.02e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—EGFR—urinary bladder cancer	1.33e-05	9.01e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—EGFR—urinary bladder cancer	1.33e-05	9e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—EGFR—urinary bladder cancer	1.33e-05	8.97e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—EGFR—urinary bladder cancer	1.32e-05	8.94e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—EGFR—urinary bladder cancer	1.31e-05	8.85e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—EGFR—urinary bladder cancer	1.31e-05	8.83e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—TP53—urinary bladder cancer	1.29e-05	8.72e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—HRAS—urinary bladder cancer	1.28e-05	8.68e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—KRAS—urinary bladder cancer	1.28e-05	8.65e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—KRAS—urinary bladder cancer	1.26e-05	8.52e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—KRAS—urinary bladder cancer	1.26e-05	8.5e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—TP53—urinary bladder cancer	1.25e-05	8.48e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—KRAS—urinary bladder cancer	1.25e-05	8.47e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—KRAS—urinary bladder cancer	1.25e-05	8.44e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—MYC—urinary bladder cancer	1.24e-05	8.38e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—KRAS—urinary bladder cancer	1.24e-05	8.36e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—TP53—urinary bladder cancer	1.24e-05	8.34e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—KRAS—urinary bladder cancer	1.23e-05	8.34e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—HRAS—urinary bladder cancer	1.23e-05	8.34e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—EGFR—urinary bladder cancer	1.21e-05	8.2e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—HRAS—urinary bladder cancer	1.2e-05	8.11e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—HRAS—urinary bladder cancer	1.18e-05	7.98e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.16e-05	7.86e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—KRAS—urinary bladder cancer	1.15e-05	7.75e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—TP53—urinary bladder cancer	1.14e-05	7.69e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	1.13e-05	7.64e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—TP53—urinary bladder cancer	1.12e-05	7.57e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—TP53—urinary bladder cancer	1.12e-05	7.55e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—TP53—urinary bladder cancer	1.11e-05	7.53e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—TP53—urinary bladder cancer	1.11e-05	7.5e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.11e-05	7.5e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—TP53—urinary bladder cancer	1.1e-05	7.43e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—TP53—urinary bladder cancer	1.1e-05	7.41e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—HRAS—urinary bladder cancer	1.09e-05	7.36e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—HRAS—urinary bladder cancer	1.07e-05	7.24e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—HRAS—urinary bladder cancer	1.07e-05	7.22e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—HRAS—urinary bladder cancer	1.07e-05	7.2e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—HRAS—urinary bladder cancer	1.06e-05	7.18e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—HRAS—urinary bladder cancer	1.05e-05	7.11e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—HRAS—urinary bladder cancer	1.05e-05	7.09e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—TP53—urinary bladder cancer	1.02e-05	6.89e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PTEN—urinary bladder cancer	9.86e-06	6.66e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—HRAS—urinary bladder cancer	9.75e-06	6.59e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—EP300—urinary bladder cancer	9.4e-06	6.35e-05	CbGpPWpGaD
